MenuClose
ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlightsSubscribe to the newsletter

Recent coverage

ESMO 2026On demandMadrid, October 23–27See the ESMO 2026 highlights

More tumor sites

Across disciplines

NADIM: five-year outcomesPerioperative chemotherapy plus nivolumab in resectable stage IIIA NSCLC: 5-year progression-free survival of 65%.Latest highlight, from The Lancet Oncology

The 2026 program

The OncoAlert Colloquium emblemThe OncoAlert ColloquiumThe year in review in oncology, one tumor group a day. Free for oncology professionals.

Listen to Oncology Here & Now

The newest Horizons discussionAdjuvant treatment challenges in early HR+/HER2− breast cancer, with Dr. Sibylle Loibl and Dr. Rupert Bartsch.

Videos

Expert picks on video, in the order we post them.

Show news for

October 2026

  1. HARMONi-GI1: Ivonescimab Improves Survival in Biliary Tract Cancer | ESMO 2026

    Gastrointestinal. Dr. Vilma Barcia. ESMO 2026.

  2. DASL-HiCaP: Darolutamida melhora a sobrevida livre de metástases no câncer de próstata | ESMO 2026

    Genitourinary. ESMO 2026.

  3. LITESPARK-011 : Belzutifan + Lenvatinib vs Cabozantinib After IO in RCC | Dr. Daniel Heng #ESMO26

    Genitourinary. Dr. Daniel Heng. ESMO 2026.

  4. VOLGA Phase 3 Trial: Durvalumab + Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

    Genitourinary. Dr. Tom Powles. ESMO 2026.

  5. NATALEE 6-Year Update: Overall Survival Benefit With Ribociclib | ESMO 2026

    Breast. Dr. Gil Morgan. ESMO 2026.

  6. TOP-1 Trial: Can We Omit Both Radiotherapy and Endocrine Therapy?

    Breast. Dr. Elisabetta Bonzano. ESMO 2026.

  7. Can triplet combinations improve outcomes in advanced urothelial cancer?

    Genitourinary. Sara Coca Membribes. ESMO 2026.

October 2025

  1. Prostate cancer: EMBARK, CAPItello-281, PETRANHA

    Genitourinary. Dr. Gil Morgan. ESMO 2025.

  2. GI oncology: NICHE-2 and STELLAR-303

    Gastrointestinal. Dr. Nicholas Hornstein. ESMO 2025.

  3. Kidney cancer: RAMPART, O3A and OPTIC

    Genitourinary. Dr. Brian Rini. ESMO 2025.

  4. Lung cancer: the picks from Berlin

    Lung and thoracic. Dr. Biagio Ricciuti. ESMO 2025.

  5. OPTIC RCC: a biomarker-selected combination

    Genitourinary. Dr. Brian Rini. ESMO 2025.

  6. Breast cancer: the picks from Berlin

    Breast. Dr. Elisa Agostinetto. ESMO 2025.

  7. DISCUS (LBA 109): three or six cycles before avelumab

    Genitourinary. Dr. Enrique Grande. ESMO 2025.

  8. HARMONi-6: ivonescimab in squamous NSCLC

    Lung and thoracic. Dr. Hidehito Horinouchi. ESMO 2025.

  9. IMvigor011: ctDNA after cystectomy

    Genitourinary. Dr. Tom Powles. ESMO 2025.

June 2025

  1. Prostate cancer at ASCO 2025

    Genitourinary. Dr. Natalia Gandur. ASCO 2025. In Spanish.

  2. Metastatic castration-resistant prostate cancer at ASCO 2025

    Genitourinary. Dr. Natalia Gandur. ASCO 2025. In Spanish.